THURSDAY, Sept. 12, 2024 (HealthDay News) -- It could be a real breakthrough for people at risk for HIV infection: A shot ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

More encouraging news has been announced about the new, twice-yearly PrEP injection currently undergoing trials. Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead ...

The findings reveal that administering Depemokimab twice yearly significantly lowers the annualized rate of asthma ...

we can deliver twice-yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP.” While the results are good news, the drug is expensive. The National Institutes of Health have ...

Lenacapavir, a twice-yearly injectable antiretroviral, reduced the risk of HIV infection by 96% in a large study of gay and bisexual men and gender diverse people, according to a Gilead Sciences ...

Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.

This week, young people are making disasters their own through memes, convincing their boyfriends to do interpretive dance, ...

In response to increased criticism of its pricing, Gilead Sciences has reached voluntary licensing deals with companies to make generic versions of its twice-yearly HIV medicine, lenacapavir ...